Smith, Graham & Co., Investment Advisors, LP Ligand Pharmaceuticals Inc Transaction History

Smith, Graham & Co., Investment Advisors, LP

$867 Million
Q4 2023

A detailed history of Smith, Graham & Co., Investment Advisors, LP transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Smith, Graham & Co., Investment Advisors, LP holds 83,121 shares of LGND stock, worth $9.53 Million. This represents 0.68% of its overall portfolio holdings.

Number of Shares

83,121

Previous 61,849 34.39%

Holding current value

$9.53 Million

Previous $3.71 Million 60.22%

% of portfolio

0.68%

Previous 0.46%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 29, 2024	BUY	$49.57 - $72.63 $1.05 Million - $1.54 Million	21,272 Added 34.39%	83,121 $5.94 Million
Q3 2023 Nov 07, 2023	SELL	$58.86 - $72.67 $34,550 - $42,657	-587 Reduced 0.94%	61,849 $3.71 Million
Q2 2023 Jul 31, 2023	SELL	$69.53 - $79.33 $189,608 - $216,332	-2,727 Reduced 4.18%	62,436 $4.5 Million
Q1 2023 May 09, 2023	SELL	$65.67 - $77.08 $13,725 - $16,109	-209 Reduced 0.32%	65,163 $4.79 Million
Q4 2022 Feb 02, 2023	SELL	$61.72 - $96.74 $1.26 Million - $1.98 Million	-20,485 Reduced 23.86%	65,372 $4.37 Million
Q3 2022 Nov 04, 2022	SELL	$0.01 - $107.56 $1 - $12,692	-118 Reduced 0.14%	85,857 $7.39 Million
Q2 2022 Aug 04, 2022	SELL	$74.52 - $117.06 $64,012 - $100,554	-859 Reduced 0.99%	85,975 $7.67 Million
Q1 2022 May 06, 2022	SELL	$94.99 - $151.56 $53,004 - $84,570	-558 Reduced 0.64%	86,834 $9.77 Million
Q4 2021 Jan 26, 2022	SELL	$127.69 - $165.85 $900,342 - $1.17 Million	-7,051 Reduced 7.47%	87,392 $13.5 Million
Q3 2021 Nov 01, 2021	SELL	$102.33 - $144.73 $403,691 - $570,959	-3,945 Reduced 4.01%	94,443 $13.2 Million
Q2 2021 Aug 09, 2021	SELL	$113.03 - $155.64 $396,848 - $546,452	-3,511 Reduced 3.45%	98,388 $12.9 Million
Q1 2021 Apr 27, 2021	BUY	$99.52 - $215.83 $433,608 - $940,371	4,357 Added 4.47%	101,899 $15.5 Million
Q4 2020 Jan 20, 2021	BUY	$80.55 - $106.05 $1.92 Million - $2.53 Million	23,813 Added 32.3%	97,542 $9.7 Million
Q3 2020 Oct 27, 2020	BUY	$89.56 - $126.72 $6.6 Million - $9.34 Million	73,729 New	73,729 $7.03 Million

Others Institutions Holding LGND

# of Institutions

256

Shares Held

18.1M

Call Options Held

26.8K

Put Options Held

9.3K

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.94B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith, Graham & Co., Investment Advisors, LP, based on Form 13F filings with the SEC.

News

Stay updated on Smith, Graham & Co., Investment Advisors, LP with notifications on news.

Account

Smith, Graham & Co., Investment Advisors, LP Ligand Pharmaceuticals Inc Transaction History